*CARADERM, French Network of Rare Cutaneous Cancer
†Department of Pathology, University Hospital Center of Tours
‡“Biologie des infections polyomavirus” Team, UMR INRA ISP1282, University of Tours
§Platform of Solid Tumor Molecular Genetics, University Hospital Center of Tours, Tours
∥Department of Pathology, APHM, Timone University Hospital
¶Aix Marseille University, INSERM, MMG, UMR1251, Marmara Institute, Marseille
#Department of Biopathology, Center Léon Bérard
**University of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer
¶¶Department of Pathology, University Hospital Center of Lyon-Sud, Hospices Civils de Lyon, Lyon
††French National Center for Scientific Research (CNRS), Laboratory MIVEGEC (CNRS IRD Univ Montpellier), Montpellier
‡‡Institut Curie, PSL Research University, CNRS UMR3244
§§Faculté de Médecine Paris Centre Santé, University of Paris
∥∥Department of Pathology, Cochin Hospital, AP-HP, AP-HP Centre-Université de Paris
†††Cabinet Mathurin Moreau
‡‡‡Department of Pathology, Hôpital Ambroise Pare, AP-HP
∥∥∥∥Department of Pathology, Hopital Saint Louis, AP-HP Universite ́ Paris 7, Paris
##National Center of Dermatopathology, Paris-la Roquette, Ivry
***Department of Pathology, University Hospital Center of Bordeaux, Pessac
§§§Department of Pathology, CHU Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole
∥∥∥Université Toulouse III Paul Sabatier, Toulouse
###Department of Pathology, University Hospital Center of Poitiers, LITEC, UR 15560, University of Poitiers, Poitiers
††††Department of Dermatology, Hospital Center of Pau, Pau
‡‡‡‡Department of Dermatology, University Hospital Center of Lille, Lille
§§§§Clinique Dermatologique, Hôpitaux Universitaires & Université de Strasbourg, Hôpital Civil, Strasbourg, France
¶¶¶Laboratory of Experimental Pathology, GIGA-Cancer, University of Liège, Liège, Belgium
****Dermatopathology Laboratory, St John’s Institute of Dermatology, St Thomas’ Hospital, London, UK
T.K., A.T., and M.B.: performed study concept and design. T.K., A.T., and M.B.: performed development of methodology and writing, review and revision of the paper. N.M., A.d.l.F., D.P., F.T., I.G.B., A.N., S.B., P.S., B. Balme, I.M., B. Bonsang, M.H., A.Z., E.C., A.T., A.S., E.F., L.M., and T.J.: provided acquisition, analysis and interpretation of data, and statistical analysis. A.d.l.F., D.P., and F.T.: provided technical and material support. All authors read and approved the final paper.
Conflicts of Interest and Source of Funding: Supported by the CARADERM Network. High-throughput sequencing was performed by the ICGex NGS platform of the Institut Curie supported by the grants ANR-10-EQPX-03 (Equipex) and ANR-10-INBS-09-08 (France Génomique Consortium) from the Agence Nationale de la Recherche (“Investissements d’Avenir” program), by the ITMO-Cancer Aviesan (Plan Cancer III) and by the SiRIC-Curie program (SiRIC Grant INCa-DGOS- 465 and INCa-DGOS-Inserm_12554). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
Correspondence: Thibault Kervarrec, MD, PhD, Department of Pathology, Hôpital Trousseau, CHRU de Tours, Tours 37044, France (e-mail: [email protected]).
Supplemental Digital Content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal's website, www.ajsp.com.
